$ERAS pan-Ras data update this afternoon after market close. also, $RVMD sent Erasca a letter claiming ERAS-0015 violates certain RevMed patents. https://t.co/QTmyUhT89n
@Sanctuary_Bio @a_a_free @JacobPlieth Agreed. I do wonder if there's a chance $RVMD gets a first-line PDAC label faster than we expect. I don't know how that would work, but these days, can you discount it entirely?
@Banana_Oncology As I mentioned, companies usually set their own benchmark for a reason. What will you use from $RVMD as a comparator to the upcoming $ERAS data?
This week's Biotech Scorecard: Erasca $ERAS is the poor man's $RVMD (even tho $7B is far from impoverished) Can it be biotech's next big thing? Pan-Ras data next month, right in front of #ASCO26 abstract drop. I spoke to CEO Jon Lim... https://t.co/GckT7X7jdN
From $RVMD Revolution Medicines, more strong data on KRAS drug and a glimpse of a ‘novel class’ beyond it Last night's RM-055 data at #AACR26 https://t.co/pfbsXZcOKg via @angRchen
At AACR, more strong results for Revolution Medicine’s KRAS drug, plus assurance from NCI’s director https://t.co/YngPC1Aol2 via @statnews #AACR26 $RVMD
#ASCO26 abstract titles were released today: $RVMD RASolute Ph3 study in pancreatic cancer will be presented during the plenary session. Also, Akeso $SMMT ivonescimab HARMONi-6 trial in lung cancer. China-only data.
The race to catch KRAS, pancreatic cancer’s ‘greasy ball,’ and create the most promising drug in decades Or, how $RVMD is now worth $30B https://t.co/iFilUpezjn via @angRchen #AACR26
@Sanctuary_Bio That said, over the past 6 months $ERAS has been a far better trade than $RVMD. With an asset bought for $12.5m. Unreal!
@Sanctuary_Bio I don't know how many EQRX holders are still in this stock, but what a ride they've had! Probably done better than had they followed the (highly commendable) goal of trying to disrupt US drug pricing $RVMD
Why $RVMD & $ALLO are a microcosm of biotech's historic struggle for success. Some musings from me on @ApexOnco -> https://t.co/3lWgzQplvc
$RVMD raised $2 billion!
How did I miss this moron’s $RVMD tweet from earlier today? I’m not on my game. https://t.co/Wy6jmUueMV
Financings: $ALLO $175M $RVMD $750M + $250M in notes.
Today's $RVMD study outcome in pancreatic cancer is a good lesson for all the $IBRX @DrPatrick fans. Stop with all the hand-waving "cancer cure" podcasting social media nonsense. Shut up and run well-designed clinical trials with definitive endpoints. If you have a drug that truly helps patients, the data will speak loudly for you.
Has $RVMD won #AACR26 already?
As noted by others, the $RVMD dara mOS in 2nd line PDAC is better than mOS for current first-line regimens.
The $RVMD press release is here: Especially noteworthy given the recent Ben Sasse interview. https://t.co/akHMba2BE7
STAT's story on this very strong $RVMD pancreatic cancer study outcome, albeit with limited data disclosure for now, from @Jasonmmast https://t.co/m19srsEvcU
Finally, best news of the morning (and something you didn't expect so soon)... Revolution Medicines $RVMD daraxonrasib Ph3 results in second-line pancreatic cancer. Median overall survival in ITT patients (KRAS mutants + wild type combined) Dara 13.2 months vs chemo 6.7 months. OS Hazard ratio 0.40
$MRK's PD-1 x VEGF bispecific reveal, & other key #AACR26 presentations, via @APEXONCO -> https://t.co/ob1eswxCWF $RVMD $AMGN $GILD $BCYC $SDGR
One $INCY Kras G12D inhibitor goes on clinical hold, the other ends recruitment after hitting just 10% of its enrolment target. Scoop via @ApexOnco -> https://t.co/zy6Y8Z9toE $MRK $RVMD $ALPMF
$RVMD was collaborating with $TNGX in PRMT5, but now it's working with $BMY (remember that ex MRTX project?). Via @ByMadeleineA @ApexOnco -> https://t.co/mGZjKOiB7p (And $AMGN still dose optimising.)
WSJ: $MRK $RVMD deal off https://t.co/OD4cueoX04
Reporting from inside the room... With a grin — and tight lips — Revolution Medicines’ $RVMD CEO faces questions about acquisition https://t.co/75ftdUF2Jh #JPM26
$RVMD CEO Mark Goldsmith’s presentation delivery is dry, matter of fact. It is NOT titled “Why Merck (or someone) will pay $30B for us” but it could be. #JPM26
The $RVMD room is packed. #JPM26
$RVMD CEO Mark Goldsmith will present Monday morning at #JPM26, spokesperson tells me. A couple of investors have also told me they’re attending a private RevMed group lunch on Monday, too. I guess Mark simply didn’t want to meet with me. ☹️🤷🏻
$RVMD - I had a meeting scheduled with the CEO on Monday morning. The company just cancelled. #JPM26 RevMed is also scheduled to present at the conference on Monday morning. I assume that’s cancelled, too, but I don’t have confirmation.
@bio_clouseau Seems that there's a lot of scope for $MRK to look silly here $RVMD
@bio_clouseau It's good if leaking the deal raises the share price and causes the buyer to pay more, which was presumably the aim of $RVMD and/or its bankers when they leaked it. But $ABBV told them where to go, so in that case the leak backfired.
Our man @mroliverbarnes $MRK $RVMD https://t.co/vUssAaRo5e US pharmaceutical group Merck is in talks to buy Revolution Medicines, a cancer drugmaker with a market capitalisation of nearly $19bn, in what would be the latest big deal in the red-hot biotechnology sector. Merck has been pursuing an acquisition of Revolution Medicines, however a deal has not been finalised, according to people familiar with the matter. A tie-up would be at least several weeks away, they added. Other large pharmaceutical groups were still circling the Redwood City-based biotech and another suitor might yet prevail, the people added. A transaction is not a foregone conclusion.
No $ABBV $RVMD deal, per an Abbvie spokesperson, per Bloomberg. Huh...
$ABBV taking out $RVMD would certainly check the #JPM26 big M&A box. $20B plus deal.
$ABBV in advanced talks to acquire $RVMD, per WSJ
$AZN follows $LLY $PFE $AMGN $ONC & $ALPMF into pan-KRAS, but should it be looking more to pan-RAS approaches like $RVMD & $ERAS? Via @ApexOnco -> https://t.co/MioOWziuSt
@NotGenentech @bioinvestor24 Here's a list of just the clinical pan-RAS & pan-KRAS assets from Oncologypipeline $RVMD $LLY $ONC $RHHBY $PFE $ERAS $AZN $AMGN $ALPMF https://t.co/oeb4Yr2nzo
@s86CoffeeDev @houndcl @financebully @avidresearch @Banana_Oncology $ERAS says ERAS-0015 uses different scaffold vs daraxonrasib. Not sure if that circumvents $RVMD patent.
Each will comprise "dozens of patients". Goal for ERAS-0015 is "comparable" safety to $RVMD and comparable efficacy at say half daraxonrasib dose $ERAS #Jefferies25
How the first nine drug companies won priority review vouchers from Marty Makary’s FDA https://t.co/6r3UlcN8Wn via @LizzyLaw_ $DISC $RVMD $REGN $ACHV
Oh good, another Kras update from $RVMD #Targets25 https://t.co/A3MStH96tK
$RVMD RMC-6236 (pancreatic cancer) among nine drugs awarded an FDA Commissioner’s National Priority Voucher. https://t.co/Vi2p9e7y5T
$RHHBY into phase 1 with a new pan-Ras inhibitor? RG6505 can't be the same as LUNA18 (via Chugai's Epoc acquisition) as that started ph1 in 2021 $RVMD https://t.co/TIy7yIk8mH
You already have a small-molecule inhibitor, so do you also need a degrader? $ONC $BGNE thinks yes, for BTK, CDK2 & Kras. Via @ApexOnco -> https://t.co/LFJCsl1MQj $ARVN $GILD $RVMD
@NotGenentech @john_hersc79276 How does a company with $4bn in the bank and now mortgaged assets make for a more attractive takeover target than one without? $RVMD
Why? $RVMD
